|
Raw Material Medicine Manufacturing
|
US$
300 |
|
Jul-2023 |
Doc #38449 |
|
| Printed Page Length :
14
pages |
| Number of Tables :
2 |
| Number of Figures:
2 |
|
Market Overview
|
|
Taiwan’s domestic sales and export sales of active pharmaceutical ingredients for epidemics will weaken. Moreover, Chinese firms will improve their competitive edge, while the baseline is high, suggesting the industry climate will ease in the second half of 2023.
|
|
|
|